Ocumension Therapeutics
01477
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
505
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,118.80 | 2.70 | -0.03% |
CAC 40 | 7,895.94 | 15.07 | 0.19% |
DAX 40 | 23,880.72 | 135.66 | 0.57% |
Dow JONES (US) | 46,397.89 | 81.82 | 0.18% |
FTSE 100 | 9,350.43 | 50.59 | 0.54% |
HKSE | 26,855.56 | 232.68 | 0.87% |
NASDAQ | 22,660.01 | 68.86 | 0.30% |
Nikkei 225 | 44,489.40 | 443.23 | -0.99% |
NZX 50 Index | 13,341.61 | 49.25 | 0.37% |
S&P 500 | 6,688.46 | 27.25 | 0.41% |
S&P/ASX 200 | 8,828.90 | 4.50 | -0.05% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |